Clinical Trial

Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is to determine if Healthy Donor FMT (hdFMT) improves the body's ability to fight cancer in patients with relapsed/refractory PD-L1 Positive NSCLC.
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2022-12-20; most recent amendment 2026-03-19.
Status change: Not Yet Recruiting → Recruiting 2024-12-23
Trial Details
NCT Number NCT05669846
Lead Sponsor Diwakar Davar
Collaborators: Gateway for Cancer Research
Conditions Non Small Cell Lung Cancer
Enrollment 26 participants
Start Date 2025-01-08
Primary Completion 2036-12-31 (estimated)
Study Completion 2036-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-23